MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME).
Petty, Robert D, McCarthy, Neil E, Le Dieu, Rifca et al. · PloS one · 2016 · DOI
Quick Summary
This study examined tiny molecules called microRNAs in immune cells from ME/CFS patients and healthy people. Researchers found that four specific microRNAs were abnormally high in patients' blood, particularly in natural killer (NK) immune cells. When they tested these microRNAs in the lab, they found they affected how NK cells work, suggesting this might contribute to ME/CFS symptoms.
Why It Matters
This work identifies potential blood-based diagnostic biomarkers for ME/CFS—a disease without approved biomarkers—and provides mechanistic insight into how NK cell dysfunction may contribute to pathology. Understanding the role of microRNAs in immune dysregulation could open new avenues for both diagnosis and targeted therapeutic interventions.
Observed Findings
Four microRNAs (hsa-miR-99b, hsa-miR-330-3p, hsa-miR-126, hsa-miR-30c) showed consistently elevated expression in ME/CFS patients' blood cells compared to controls.
NK cells exhibited the most significant microRNA deregulation compared to B cells and monocytes.
Transfecting primary NK cells with hsa-miR-99b and hsa-miR-330-3p induced markers of cellular activation.
These microRNA transfections were associated with reduced NK cell cytotoxic function despite activation markers.
Inferred Conclusions
Aberrant microRNA expression in NK cells may contribute to impaired immune function in ME/CFS.
These four microRNAs could serve as potential diagnostic biomarkers detectable in peripheral blood.
NK cell dysfunction involving altered microRNA regulation may be mechanistically important in ME/CFS pathogenesis.
Remaining Questions
Do these microRNA changes precede disease onset, persist during remission, or fluctuate with symptom severity?
What upstream factors drive the upregulation of these microRNAs in ME/CFS patients?
Would therapeutic approaches targeting these microRNAs restore NK cell function and improve clinical outcomes?
What This Study Does Not Prove
This study does not prove that these microRNAs cause ME/CFS; it only shows they are associated with the disease. The findings are correlational and based on in vitro functional studies, not evidence that correcting these microRNAs would improve patient outcomes. Additionally, the mechanisms linking NK cell dysfunction to systemic ME/CFS symptoms remain unclear.